Scleroderma screening

Scleroderma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scleroderma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scleroderma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scleroderma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scleroderma screening

CDC on Scleroderma screening

Scleroderma screening in the news

Blogs on Scleroderma screening

Directions to Hospitals Treating Scleroderma

Risk calculators and risk factors for Scleroderma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  M. Khurram Afzal, MD [2]

## Overview[edit | edit source]

There is insufficient evidence to recommend routine screening for scleroderma, however screening is recommended for pulmonary arterial hypertension and malignancy in scleroderma patients. Regular blood pressure monitoring at home is encouraged in patients with scleroderma to screen for renal involvement and prevention of scleroderma renal crisis.

## Screening[edit | edit source]

There is insufficient evidence to recommend routine screening for scleroderma, however screening is recommended for pulmonary arterial hypertension and malignancy in scleroderma patients:

* According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.[1][2]
* Enhanced screening for malignancy is recommended in scleroderma patients at high risk.[3]
* Regular blood pressure monitoring at home is encouraged in patients with scleroderma to screen for renal involvement and prevention of scleroderma renal crisis.[4]

## References[edit | edit source]

1. ↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association". J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.
2. ↑ Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). "Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension". Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.
3. ↑ Shah AA, Casciola-Rosen L (November 2015). "Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening". Curr Opin Rheumatol. 27 (6): 563–70. doi:10.1097/BOR.0000000000000222. PMC 4643720. PMID 26352736.
4. ↑ Khanna D, Denton CP (June 2010). "Evidence-based management of rapidly progressing systemic sclerosis". Best Pract Res Clin Rheumatol. 24 (3): 387–400. doi:10.1016/j.berh.2009.12.002. PMC 2884006. PMID 20534372.

Template:WH Template:WS